A critical European clinical trial has been announced that could lead to the development of less invasive and more effective treatments for neuroblastoma, a rare and aggressive childhood cancer.
The SIOPEN High-Risk Neuroblastoma Clinical Trial 2 is a Phase 3 clinical trial, funded by a grant of £609,762 that will make it the only upfront clinical trial for children in the UK diagnosed with this disease.
The University of Birmingham Cancer Research UK Clinical Trials Unit is the UK national coordinator and will be responsible for delivering the trial across sites around the country.
“It’s fantastic to have been given this opportunity by Solving Kids’ Cancer and Neuroblastoma UK to bring this trial to UK neuroblastoma patients.
“We are grateful for the hard work of our UK investigators in our successful grant application and we look forward to working with them to open the trial for patients in early 2021,” Dr Emma Pond, solving Kids’ Cancer senior trial coordinator, said.
Approximately 100 children a year in the UK are diagnosed with this form of cancer, with around half classified as high risk. The majority of those diagnosed are under the age of five and long-term survival from the high-risk form is still between 40 and 50 per cent, despite intensive multi-modal therapy.
The cancer is commonly found in the adrenal glands, but it can also develop elsewhere, such as some parts of the abdomen, as well as in the chest, neck and spine.
Symptoms depend on which part of the body is afflicted, but include abdominal pain, changes in bowel habits,wheezing, chest pain, back pain and changes to the eyes, such as drooping eyelids and unequal pupil sizes.
Looking for UK animal research jobs? Get in touch with us today.